Clinical Trial Update: Memantine Augmentation of Targeted Cognitive Training in Schizophrenia [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluating memantine added to targeted cognitive training for schizophrenia and schizoaffective disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Namenda (memantine)

Snippet

Sponsor: University of California, San Diego | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2, Phase 3 | Status: COMPLETED